Thiazolidinedione-dependent activation of sphingosine kinase 1 causes an anti-fibrotic effect in renal mesangial cells

British Journal of Pharmacology

Volumn 166, Issue 3, 2012, Pages 1018-1032

  Koch, A ^a   Volzke A ^a   Wunsche C ^a   Meyer Zu Heringdorf, D ^a   Huwiler, A ^b   Pfeilschifter, J ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

connective tissue growth factor; mesangial cell; sphingosine kinase; sphingosine 1 phosphate; thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CONNECTIVE TISSUE GROWTH FACTOR; MESSENGER RNA; ROSIGLITAZONE; SPHINGOSINE KINASE 1; TROGLITAZONE;

ANIMAL CELL; ANTIFIBROTIC ACTIVITY; ARTICLE; CELL ISOLATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; GLOMERULUS; KIDNEY FIBROSIS; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; TRANSCRIPTION REGULATION; UPREGULATION; WILD TYPE;

ANIMALS; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CONNECTIVE TISSUE GROWTH FACTOR; ENZYME ACTIVATION; FEMALE; FIBROSIS; HUMANS; LYSOPHOSPHOLIPIDS; MESANGIAL CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTAGENESIS, SITE-DIRECTED; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PPAR GAMMA; PROMOTER REGIONS, GENETIC; RATS; REAL-TIME POLYMERASE CHAIN REACTION; SPHINGOSINE; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 84860879198     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01824.x     Document Type: Article

References (56)

1. Abdel Wahab N, Mason RM, (2004). Connective tissue growth factor and renal diseases: some answers, more questions. Curr Opin Nephrol Hypertens 13: 53-58.
2. Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, et al,. (2010). Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 465: 1084-1088.
3. Boor P, Sebeková K, Ostendorf T, Floege J, (2007). Treatment targets in renal fibrosis. Nephrol Dial Transplant 22: 3391-3407.
4. Bork P, (1993). The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 327: 125-130.
5. Chien W, Yin D, Gui D, Mori A, Frank JM, Said J, et al,. (2006). Suppression of cell proliferation and signaling transduction by connective tissue growth factor in non-small cell lung cancer cells. Mol Cancer Res 4: 591-598.
6. Choi JH, Banks AS, Estall JL, Kajimura S, Boström P, Laznik D, et al,. (2010). Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466: 451-456.
7. Crean JK, Furlong F, Finlay D, Mitchell D, Murphy M, Conway B, et al,. (2004). Connective tissue growth factor [CTGF]/CCN2 stimulates mesangial cell migration through integrated dissolution of focal adhesion complexes and activation of cell polarization. FASEB J 18: 1541-1543.
8. Desvergne B, Wahli W, (1999). Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20: 649-688.
9. Dornhofer N, Spong S, Bennewith K, Salim A, Klaus S, Kambham N, et al,. (2006). Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 66: 5816-5827.
10. Francki A, Uciechowski P, Floege J, von der Ohe J, Resch K, Radeke HH, (1995). Autocrine growth regulation of human glomerular mesangial cells is primarily mediated by basic fibroblast growth factor. Am J Pathol 147: 1372-1382.
11. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, et al,. (2003). Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 63: 5962-5969.
12. French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD, (2006). Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 318: 596-603.
13. Fu M, Zhang J, Zhu X, Myles DE, Willson TM, Liu X, et al,. (2001). Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3. J Biol Chem 276: 45888-45894.
14. Gupta S, Clarkson MR, Duggan J, Brady HR, (2000). Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 58: 1389-1399.
15. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al,. (2009). Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 325: 1254-1257.
16. Hla T, (2003). Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res 47: 401-407.
17. Hofmann LP, Ren S, Schwalm S, Pfeilschifter J, Huwiler A, (2008). Sphingosine kinase 1 and 2 regulate the capacity of mesangial cells to resist apoptotic stimuli in an opposing manner. Biol Chem 389: 1399-1407.
18. Houtkooper RH, Auwerx J, (2010). Obesity: new life for antidiabetic drugs. Nature 466: 443-444.
19. Huwiler A, Stabel S, Fabbro D, Pfeilschifter J, (1995). Platelet-derived growth factor and angiotensin II stimulate the mitogen-activated protein kinase cascade in renal mesangial cells: comparison of hypertrophic and hyperplastic agonists. Biochem J 305: 777-784.
20. Huwiler A, Kolter T, Pfeilschifter J, Sandhoff K, (2000). Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta 1485: 63-99.
21. Huwiler A, Döll F, Ren S, Klawitter S, Greening A, Römer I, et al,. (2006). Histamine increases sphingosine kinase-1 expression and activity in the human arterial endothelial cell line EA.hy 926 by a PKC-alpha-dependent mechanism. Biochim Biophys Acta 1761: 367-376.
22. Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa R, (2000). Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 49: 1022-1032.
23. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, et al,. (2009). PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 89: 47-58.
24. Koch A, König B, Stangl GI, Eder K, (2008). PPAR alpha mediates transcriptional upregulation of novel organic cation transportes-2 and -3 and enzymes involved in hepatic carnitine synthesis. Exp Biol Med (Maywood) 233: 356-365.
25. Leask A, Abraham DJ, (2004). TGF-beta signaling and the fibrotic response. FASEB J 18: 816-827.
26. min/+ mice. Nat Med 4: 1053-1057.
27. Lehrke M, Lazar MA, (2005). The many faces of PPARgamma. Cell 123: 993-999.
28. Li MH, Sanchez T, Pappalardo A, Lynch KR, Hla T, Ferrer F, (2008). Induction of antiproliferative connective tissue growth factor expression in Wilms' tumor cells by sphingosine-1-phosphate receptor 2. Mol Cancer Res 6: 1649-1656.
29. Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S, et al,. (2000). Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 275: 19513-19520.
30. Long DA, Price KL, (2009). Sphingosine kinase-1: a potential mediator of renal fibrosis. Kidney Int 76: 815-817.
31. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB, (2001). Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 59: 1899-1910.
32. Madry H, Reszka R, Bohlender J, Wagner J, (2001). Efficacy of cationic liposome-mediated gene transfer to mesangial cells in vitro and in vivo. J Mol Med 79: 184-189.
33. Melendez AJ, Carlos-Dias E, Gosink M, Allen JM, Takacs L, (2000). Human sphingosine kinase: molecular cloning, functional characterization and tissue distribution. Gene 251: 19-26.
34. Miglio G, Rosa AC, Rattazzi L, Grange C, Collino M, Camussi G, et al,. (2011). The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury. Br J Pharmacol 162: 111-125.
35. Minucci S, Pelicci PG, (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
36. Nakade Y, Banno Y, T-Koizumi K, Hagiwara K, Sobue S, Koda M, et al,. (2003). Regulation of sphingosine kinase 1 gene expression by protein kinase C in a human leukemia cell line, MEG-O1. Biochim Biophys Acta 1635: 104-116.
37. Nissen SE, Wolski K, (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471.
38. Pfeilschifter J, Vosbeck K, (1991). Transforming growth factor beta 2 inhibits interleukin 1 beta- and tumour necrosis factor alpha-induction of nitric oxide synthase in rat renal mesangial cells. Biochem Biophys Res Commun 175: 372-379.
39. Pyne NJ, Pyne S, (2010). Sphingosine 1-phosphate and cancer. Nat Rev Cancer 10: 489-503.
40. Radeke HH, Meier B, Topley N, Floge J, Habermehl GG, Resch K, (1990). Interleukin 1-alpha and tumor necRSGs factor-alpha induce oxygen radical production in mesangial cells. Kidney Int 37: 767-775.
41. Ren S, Babelova A, Moreth K, Xin C, Eberhardt W, Doller A, et al,. (2009). Transforming growth factor-beta2 upregulates sphingosine kinase-1 activity, which in turn attenuates the fibrotic response to TGF-beta2 by impeding CTGF expression. Kidney Int 76: 857-867.
42. Ren S, Xin C, Pfeilschifter J, Huwiler A, (2010). A novel mode of action of the putative sphingosine kinase inhibitor 2-(p-hydroxyanilino)-4-(p- chlorophenyl) thiazole (SKI II): induction of lysosomal sphingosine kinase 1 degradation. Cell Physiol Biochem 26: 97-104.
43. Riser BL, Cortes P, DeNichilo M, Deshmukh PV, Chahal PS, Mohammed AK, et al,. (2003). Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report. Kidney Int 64: 451-458.
44. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, et al,. (1998). Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 4: 1058-1061.
45. Schnaper HW, Hayashida T, Hubchak SC, Poncelet AC, (2003). TGF-beta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol 284: 243-252.
46. Scholz-Pedretti K, Gans A, Beck KF, Pfeilschifter J, Kaszkin M, (2002). Potentiation of TNF-alpha-stimulated group IIA phospholipase A(2) expression by peroxisome proliferator-activated receptor alpha activators in rat mesangial cells. J Am Soc Nephrol 13: 611-620.
47. Schwalm S, Döll F, Römer I, Bubnova S, Pfeilschifter J, Huwiler A, (2008). Sphingosine kinase-1 is a hypoxia regulated gene that stimulates migration of human endothelial cells. Biochem Biophys Res Commun 368: 1020-1025.
48. Schwalm S, Pfeilschifter J, Huwiler A, (2010). Sphingosine kinase 1 is critically involved in nitric oxide-mediated human endothelial cell migration and tube formation. Br J Pharmacol 160: 1641-1651.
49. Tachibana K, Yamasaki D, Ishimoto K, Doi T, (2008). The role of PPARs in Cancer. PPAR Res 2008: 102737.
50. Wang L, Xing XP, Holmes A, Wadham C, Gamble JR, Vadas MA, et al,. (2005). Activation of the sphingosine kinase signaling pathway by high glucose mediates the proinflammatory phenotype of endothelial cells. Circ Res 97: 891-899.
51. Wang W, Liu F, Chen N, (2007). Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblasts. Mediators Inflamm 2007: 62641.
52. Wu J, Chen L, Zhang D, Huo M, Zhang X, Pu D, et al,. (2009). Peroxisome proliferator-activated receptors and renal diseases. Front Biosci 14: 995-1009.
53. Xin C, Ren S, Kleuser B, Shabahang S, Eberhardt W, Radeke H, et al,. (2004). Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-β-induced cell responses. J Biol Chem 279: 35255-35262.
54. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR, (2005). Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res 65: 8887-8895.
55. Yang T, Michele DE, Park J, Smart AM, Lin Z, Brosius FC, et al,. (1999). Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol 277: 966-973.
56. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, et al,. (2003). BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9: 964-968.